• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症治疗功能评估通用版(FACT-G)在接受韩医学治疗的晚期非小细胞肺癌中的预后价值

Prognostic Value of Functional Assessment of Cancer Therapy-General (FACT-G) in Advanced Non-Small-Cell Lung Cancer Treated with Korean Medicine.

作者信息

Jeon Hyeonjin, Eo Wankyu, Shim Bumsang, Kim Sehyun, Lee Sookyung

机构信息

Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.

Department of Medical Oncology & Hematology, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.

出版信息

Evid Based Complement Alternat Med. 2020 Jan 20;2020:2845401. doi: 10.1155/2020/2845401. eCollection 2020.

DOI:10.1155/2020/2845401
PMID:32454853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7212313/
Abstract

OBJECTIVES

The impact of health-related quality of life (HRQoL) on survival has been investigated in patients with various cancers. Here, we evaluated the prognostic value of HRQoL using the Functional Assessment of Cancer Therapy-General (FACT-G) in advanced non-small-cell lung cancer (NSCLC) patients treated with Korean medicine.

METHODS

A retrospective review of medical records and FACT-G scores of patients with advanced NSCLC who received treatment with Korean medicine was conducted. The reliability of the FACT-G was determined using Cronbach's alpha and calculating floor-and-ceiling effects. Correlations between FACT-G scores were estimated using Pearson's correlation analysis. Overall survival was calculated using the Kaplan-Meier method, and the prognostic impact of FACT-G scores and patients' characteristics was evaluated with Cox proportional hazards regression.

RESULTS

Of the 165 enrolled patients, 115 (70%) had extrathoracic metastasis and 139 (84%) had undergone prior anticancer treatment. The median overall survival was 10.1 months. The mean FACT-G score was 65.0, and Cronbach's alpha for the FACT-G was 0.917. Age ≥65 years, male sex, smoking history, squamous-cell carcinoma, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥2, and presence of extrathoracic metastasis were associated with an increased risk of mortality. High FACT-G total scores, physical well-being (PWB), emotional well-being, and functional well-being were associated with prolonged survival. After adjusting for age, sex, smoking history, ECOG-PS, histological type, and presence of extrathoracic metastasis, a high FACT-G total score (hazard ratio (HR): 0.99, =0.032) and high PWB score (HR: 0.94, < 0.001) were associated with prolonged survival as independent prognostic factors in patients with advanced NSCLC.

CONCLUSION

The FACT-G total score and PWB score as HRQoL measurements were significant prognostic factors for survival in advanced NSCLC patients treated with Korean medicine. This finding implies that the FACT-G can be used in clinical practice as a predictor of survival in patients with advanced NSCLC.

摘要

目的

已在各类癌症患者中研究了健康相关生活质量(HRQoL)对生存的影响。在此,我们使用癌症治疗通用功能评估量表(FACT - G)评估了接受韩医学治疗的晚期非小细胞肺癌(NSCLC)患者中HRQoL的预后价值。

方法

对接受韩医学治疗的晚期NSCLC患者的病历和FACT - G评分进行回顾性分析。使用Cronbach's α系数并计算地板效应和天花板效应来确定FACT - G的可靠性。使用Pearson相关分析估计FACT - G评分之间的相关性。采用Kaplan - Meier法计算总生存期,并通过Cox比例风险回归评估FACT - G评分和患者特征的预后影响。

结果

在165例入组患者中,115例(70%)有胸外转移,139例(84%)曾接受过抗癌治疗。中位总生存期为10.1个月。FACT - G平均评分为65.0,FACT - G的Cronbach's α系数为0.917。年龄≥65岁、男性、吸烟史、鳞状细胞癌、东部肿瘤协作组体能状态(ECOG - PS)≥2以及存在胸外转移与死亡风险增加相关。FACT - G总分、生理健康(PWB)、情绪健康和功能健康得分高与生存期延长相关。在调整年龄、性别、吸烟史、ECOG - PS、组织学类型和胸外转移情况后,FACT - G总分高(风险比(HR):0.99, =0.032)和PWB得分高(HR:0.94, < 0.001)作为独立预后因素与晚期NSCLC患者生存期延长相关。

结论

作为HRQoL测量指标的FACT - G总分和PWB得分是接受韩医学治疗的晚期NSCLC患者生存的重要预后因素。这一发现表明FACT - G可在临床实践中用作晚期NSCLC患者生存的预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/708a/7212313/43795bfe2444/ECAM2020-2845401.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/708a/7212313/43795bfe2444/ECAM2020-2845401.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/708a/7212313/43795bfe2444/ECAM2020-2845401.001.jpg

相似文献

1
Prognostic Value of Functional Assessment of Cancer Therapy-General (FACT-G) in Advanced Non-Small-Cell Lung Cancer Treated with Korean Medicine.癌症治疗功能评估通用版(FACT-G)在接受韩医学治疗的晚期非小细胞肺癌中的预后价值
Evid Based Complement Alternat Med. 2020 Jan 20;2020:2845401. doi: 10.1155/2020/2845401. eCollection 2020.
2
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.广泛期小细胞肺癌患者接受培美曲塞加卡铂与依托泊苷加卡铂治疗的预后因素:基线生活质量和体能状态。
Lung Cancer. 2012 Dec;78(3):276-81. doi: 10.1016/j.lungcan.2012.09.002. Epub 2012 Oct 6.
3
The Relationship Between Health-Related Quality of Life and Survival in Metastatic Colorectal Cancer Patients Treated With Korean Medicine.接受韩医学治疗的转移性结直肠癌患者健康相关生活质量与生存之间的关系
Integr Cancer Ther. 2018 Mar;17(1):65-72. doi: 10.1177/1534735416684015. Epub 2016 Dec 26.
4
Prognostic factors for survival in a Chinese population presenting with advanced non-small cell lung cancer with an emphasis on smoking status: A regional, single-institution, retrospective analysis of 4552 patients.以吸烟状况为重点的中国晚期非小细胞肺癌患者生存预后因素:一项对4552例患者的地区性单机构回顾性分析。
Thorac Cancer. 2012 May;3(2):162-168. doi: 10.1111/j.1759-7714.2011.00099.x.
5
Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.生活质量评分作为晚期头颈部癌症总生存的预后因素:培美曲塞联合顺铂与顺铂单药治疗的 III 期随机试验分析。
Oral Oncol. 2012 Aug;48(8):723-9. doi: 10.1016/j.oraloncology.2012.02.016. Epub 2012 Mar 11.
6
Can Nutritional Status Predict Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer?营养状况能否预测晚期非小细胞肺癌患者的总生存期?
Nutr Cancer. 2019;71(7):1108-1117. doi: 10.1080/01635581.2019.1598564. Epub 2019 Apr 22.
7
Prognostic Value of Ferritin-to-Hemoglobin Ratio in Patients with Advanced Non-Small-Cell Lung Cancer.铁蛋白与血红蛋白比值在晚期非小细胞肺癌患者中的预后价值
J Cancer. 2019 Apr 5;10(7):1717-1725. doi: 10.7150/jca.26853. eCollection 2019.
8
The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.晚期非小细胞肺癌患者临床预后因素与表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)疗效的相关性:94例EGFR突变患者的回顾性评估
Oncotarget. 2017 Jan 10;8(2):3412-3421. doi: 10.18632/oncotarget.13787.
9
Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.伽玛刀治疗肺癌脑转移瘤后生活质量和生存的预测因素:一项前瞻性研究。
J Neurosurg. 2018 Jul;129(1):71-83. doi: 10.3171/2017.2.JNS161659. Epub 2017 Aug 18.
10
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.EGFR 突变阳性的晚期非小细胞肺癌患者一线使用吉非替尼治疗的总生存预后因素的真实世界数据。
Oncologist. 2017 Sep;22(9):1075-1083. doi: 10.1634/theoncologist.2016-0331. Epub 2017 May 15.

引用本文的文献

1
Assessing the performance of QLQ-C30 in predicting all-cause mortality in community cancer patients.评估QLQ-C30在预测社区癌症患者全因死亡率方面的性能。
BMC Cancer. 2025 Mar 7;25(1):421. doi: 10.1186/s12885-025-13624-z.
2
Health-related quality of life of individuals dealing with cancer in the Free State: A survey.自由邦癌症患者的健康相关生活质量:一项调查。
S Afr J Physiother. 2025 Jan 9;81(1):2094. doi: 10.4102/sajp.v81i1.2094. eCollection 2025.
3
Quality of Life Determinants in Patients with Metastatic Prostate Cancer: Insights from a Cross-Sectional Questionnaire-Based Study.

本文引用的文献

1
NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.NCCN 指南解读:小细胞肺癌,2018 年版 2.0
J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182. doi: 10.6004/jnccn.2018.0079.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
转移性前列腺癌患者的生活质量决定因素:基于横断面问卷调查的研究结果。
Curr Oncol. 2024 Aug 26;31(9):4940-4954. doi: 10.3390/curroncol31090366.
4
Prediction of postoperative health-related quality of life among patients with metastatic spinal cord compression secondary to lung cancer.预测肺癌继发转移性脊髓压迫症患者的术后健康相关生活质量。
Front Endocrinol (Lausanne). 2023 Sep 1;14:1206840. doi: 10.3389/fendo.2023.1206840. eCollection 2023.
NCCN 指南解读:非小细胞肺癌,第 5 版,2018 年。
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821. doi: 10.6004/jnccn.2018.0062.
4
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.一项评估常规癌症治疗期间症状监测的患者报告结局的试验的总生存结果。
JAMA. 2017 Jul 11;318(2):197-198. doi: 10.1001/jama.2017.7156.
5
Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer.通用型与肺癌特异性生活质量评估工具对晚期肺癌患者生存预测能力的比较
Springerplus. 2016 Oct 21;5(1):1833. doi: 10.1186/s40064-016-3492-7. eCollection 2016.
6
Quality of life of patients with lung cancer.肺癌患者的生活质量。
Onco Targets Ther. 2016 Feb 29;9:1023-8. doi: 10.2147/OTT.S100685. eCollection 2016.
7
Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.健康相关生活质量对老年非小细胞肺癌患者总生存期的预后价值。
Eur J Cancer. 2016 Jan;52:120-8. doi: 10.1016/j.ejca.2015.10.004. Epub 2015 Dec 10.
8
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.常规癌症治疗期间通过患者报告结局进行症状监测:一项随机对照试验。
J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7.
9
The quality of life of non-small cell lung cancer patients treated with chemotherapy.接受化疗的非小细胞肺癌患者的生活质量。
Pneumonol Alergol Pol. 2014;82(4):349-57. doi: 10.5603/PiAP.2014.0044.
10
Quality of life after the initial treatments of non-small cell lung cancer: a persistent predictor for patients' survival.非小细胞肺癌初始治疗后的生活质量:对患者生存的持续预测因子。
Health Qual Life Outcomes. 2014 May 15;12:73. doi: 10.1186/1477-7525-12-73.